FARMACIA Y SALUD
Doktorandenschule
Universidad Austral de Chile
Valdivia, ChilePublikationen in Zusammenarbeit mit Forschern von Universidad Austral de Chile (12)
2016
-
A pharmacist's role in the individualization of treatment of HIV patients
Personalized Medicine, Vol. 13, Núm. 2, pp. 169-188
-
Influence of the number of daily pills and doses on adherence to antiretroviral treatment: A 7-year study
Journal of Clinical Pharmacy and Therapeutics, Vol. 41, Núm. 1, pp. 34-39
2014
-
Population pharmacokinetic/pharmacogenetic model of lopinavir/ritonavir in HIV-infected patients
Personalized Medicine, Vol. 11, Núm. 7, pp. 693-704
2013
-
Impact of a pharmaceutical care program on clinical evolution and antiretroviral treatment adherence: A 5-year study
Patient Preference and Adherence, Vol. 7, pp. 729-739
-
Nuevas estrategias en la optimización posológica de lopinavir/ritonavir en pacientes infectados por el virus de la inmunodeficiencia humana
Enfermedades Infecciosas y Microbiologia Clinica, Vol. 31, Núm. 1, pp. 36-43
2011
-
Population Pharmacokinetic/Pharmacogenetic Model for Optimization of Efavirenz Therapy in Caucasian HIV-Infected Patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Population pharmacokinetic/pharmacogenetic model for optimization of Efavirenz therapy in caucasian HIV-infected patients
Antimicrobial Agents and Chemotherapy, Vol. 55, Núm. 11, pp. 5314-5324
-
Population pharmacokinetics of lopinavir/ritonavir (kaletra) in HIV-infected patients
Therapeutic Drug Monitoring, Vol. 33, Núm. 5, pp. 573-582
2010
-
The convergence of therapeutic drug monitoring and pharmacogenetic testing to optimize efavirenz therapy
Therapeutic Drug Monitoring, Vol. 32, Núm. 5, pp. 579-585
2009
-
Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of efavirenz in human immunodeficiency virus patients
Antimicrobial Agents and Chemotherapy, Vol. 53, Núm. 7, pp. 2791-2798